Therapy News and Research

RSS

New discovery in glioma-associated metabolic changes

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome", in The Proceedings of the National Academy of Sciences.

3 Mar 2011

New research provides insight into link between sunlight, vitamin D3, MS risk and severity

New research into the neurodegenerative disease, Multiple Sclerosis offers new insight into the link between sunlight, vitamin D3, and MS risk and severity.

3 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

3 Mar 2011

Adherence counseling during HIV treatment greatly improves patient outcomes

Intensive adherence counseling around the time of HIV treatment initiation significantly reduces poor adherence and virologic treatment failure in sub-Saharan Africa, according to a recent study in PLoS Medicine by Dr. Michael Chung, assistant professor of Global Health at University of Washington, who works at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

Osiris Therapeutics, Inc., today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack.

3 Mar 2011

New microfluidic device may help clinicians to improve cancer therapy

Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.

3 Mar 2011

FDA clears Meridian's illumigene C. difficile molecular amplification test

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new pediatric claim for its illumigene C. difficile molecular amplification test. C. difficile is a bacterium that is frequently associated with antibiotic therapy often causing diarrhea and, in severe cases, a life-threatening inflammation of the colon.

2 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

GTx, Inc. today announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

2 Mar 2011

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

The National Eye Institute and Food and Drug Administration are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acuity, visual fields and contrast sensitivity.

2 Mar 2011

WARFARIN study to explore impact of genetic testing on individualized dosing

Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

2 Mar 2011

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) has completed the first two transcatheter aortic valve implants (TAVI) ever achieved in Michigan. The procedures are a part of CVI's participation in the Medtronic CoreValve® U.S. Clinical Trial. This multi-state trial will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis.

2 Mar 2011

CRT-D therapy benefits heart failure patients with left bundle branch block

Mild heart failure patients with a particular condition that results in disorganized electrical activity throughout the heart benefit substantially from cardiac resynchronization therapy with defibrillator (CRT-D), according to a study published in the American Heart Association journal Circulation.

2 Mar 2011

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).

2 Mar 2011

CRT market in Europe to reach over €4.4 billion by 2017

According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, the European cardiac rhythm management, electrophysiology and ablation market was valued at over €2.8 billion in 2010.

2 Mar 2011

Therapy News and Research

New discovery in glioma-associated metabolic changes

New research provides insight into link between sunlight, vitamin D3, MS risk and severity

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

Adherence counseling during HIV treatment greatly improves patient outcomes

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Turmeric may be 'the right spice' to fight colon cancer

Osiris completes patient enrollment in Prochymal Phase 2 trial to treat heart attack

New microfluidic device may help clinicians to improve cancer therapy

FDA clears Meridian's illumigene C. difficile molecular amplification test

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

Ipsen, Gtx terminate collaboration for development and commercialization of toremifene

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

WARFARIN study to explore impact of genetic testing on individualized dosing

DMC CVI completes the first two transcatheter aortic valve implants in Michigan

CRT-D therapy benefits heart failure patients with left bundle branch block

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

CRT market in Europe to reach over €4.4 billion by 2017

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News